immune modulatory Applications
-
Potential breakthrough treatment option for Critical Limb Ischemia (CLI)
Our First DCGI Approved Stem Cell Product: Stempeucel® is the FIRST innovative stem cell based biological product to be approved by DCGI (Indian FDA) for manufacturing and marketing for the treatment of Critical Limb Ischemia (CLI). Stempeucel® product has been licensed to Cipla in India. Stempeutics is seeking partnership for further clinical development and commercialization of Stempeucel® for Global ...
By Stempeutics Research Pvt. Ltd. based in Bangalore, INDIA.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you